Retrospective Evaluation of CML Patients in the National Compassionate Program
This observational study aims at assessing the tolerability and safety profiles of Ponatinib, a drug used for Chronic Myeloid Leukemia patients who are Philadelphia positive. This drug is used during the chronic phase of the disease, according to the Italian national compassionate law 648/96.
Chronic Myeloid Leukemia|Philadelphia Positive
DRUG: Ponatinib
Number of adverse events, General adverse events and grade 3-4 adverse events according to NCI CTCAE version 4.0, Maximum of 60 months from treatment start
Number of patients with hematological complete response, Hematological complete response and related responses, such as major cytogenetic response, complete cytogenetic response and major molecular response., Maximum of 60 months from treatment start|Number of days from treatment start till response, Maximum of 60 months from treatment start|Total number of patients alive, Overall survival, 12 months after patient enrollment in the study|Number of patients in event free survival, Event free survival, 12 months after patient enrollment in the study|Number of patients in progression free survival, Progression free survival, 12 months after patient enrollment in the study|Number of mutations, Both at the beginning and at the end of treatment, Maximum of 60 months from treatment start|Number of units of Ponatinib administered per units of time, Chemotherapy dose intensity represents unit dose of chemotherapy administered per unit time., Maximum of 60 months from treatment start
This observational study aims at assessing the tolerability and safety profiles of Ponatinib, a drug used for Chronic Myeloid Leukemia patients who are Philadelphia positive. This drug is used during the chronic phase of the disease, according to the Italian national compassionate law 648/96.